Urgent Notice to All Conference Participants

It has been brought to our attention that EHS Housing has recently been cold calling our speakers offering accommodation for a named Fusion conference. Please note that we have no association with EHS Housing and they are acting on our behalf without our permission. We strongly advise that any calls from EHS Housing are ignored or ended immediately. If you are contacted by EHS Housing, please notify us immediately.

All Fusion registration fees are inclusive of accommodation (for three fixed nights) and reservations are handled internally, entirely by Fusion Conferences. If you have any questions concerning your accommodation, please contact Fusion Conferences directly via admin@fusion-conferences.com.

Home > Past Conferences > 3rd Drug Discovery Re-Invented Conference

The registration process for this conference has now closed.

Registration Deadlines

Early bird – expired

Talk Submission – expired

Poster Submission – expired

Last Chance – expired

Past Conference

3rd Drug Discovery Re-Invented Conference

Emerging Role of Biotechs, Academics and Non-Profits

21 Feb 2017 - 24 Feb 2017

Cancun, Mexico

Synopsis

The third Drug Discovery Re-Invented Fusion series will center on new approaches to drug discovery in an industry where the landscape is changing rapidly. With large pharma reducing investment in internal early stage research, drug pipelines will increasingly be filled by alternative sources. These players include: government, academic labs, non-profits, biotech companies, and pharmaceutical “open innovation” models. The conference will also provide examples of successful strategies for advancing new drug candidates in this era of distributed discovery.

Key Sessions

  1. New Approaches in Biotech and Academia
  2. New Approaches in Pharma
  3. Natural Products
  4. Government and Non-profit Sector in Drug Discovery and Development
  5. Structure, Modeling, and Fragment-based Design
  6. Non-traditional targets and approaches
  7. Industry Exhibit
 

Chair Biographies

Dr. William A. Kinney's Bio

Dr. Kinney began his industrial career in the CNS group at Wyeth, where he invented the unique NMDA antagonist perzinfotel that progressed to phase II clinical trials for pain.  At Magainin Pharmaceuticals, he was an inventor of  trodusquemine (phase II, obesity) and squalamine (phase II, eye disease), two shark-derived natural products; and led their development from a CMC perspective.  In 2000, he joined Johnson & Johnson, where he pursued peptide-mimetic integrin antagonists and urotensin-II receptor modulators for cardiovascular indications.  He also made seminal discoveries with respect to self-assembling collagen-mimetic peptides that stimulate platelet aggregation.  Currently, Dr. Kinney is a faculty member within the Baruch S. Blumberg Institute (BSBI) and directs the Natural Product Discovery Institute (NPDI) that houses the former Merck Research Laboratories Natural Product Collection. He is an adjunct faculty member at Drexel University and Founder of IteraMed, a company focused on medicinal chemistry, drug discovery, and small business development. Dr. Kinney co-founded Revive Genomics INC, which will map out the genomic potential of the actinomycete collections.  Revive Genomics was established to apply new genomic technologies to discover novel natural products of use in pharmaceutical and agricultural industries.  Dr. Kinney’s scientific contributions include 70 publications, invited lectures, and oral presentations and inventorship on 39 issued U.S. patents.

Dr. Charles H. Reynolds' Bio

Dr. Reynolds is Founder of GFree, Bio (www.gfreebio.com), a structure-based design and modeling company.  He is an expert in the areas of computational chemistry, structure-based design, and drug discovery with a broad range of experience.  Dr. Reynolds is also a Director on the Advisory Board of Quantum Bio and an adjunct professor at the Pennsylvania Drug Discovery Institute.  Previously he was Senior Director and Head of Discovery Technologies at Ansaris (Locus).  Prior to joining Ansaris, he led modeling groups at the Springhouse, PA and La Jolla, CA research sites of Johnson & Johnson and was a Research Fellow at Rohm and Haas (now Dow).  He is a Fellow of the American Chemical Society, sits on the ACS publications committee, and is a member of the EAB for ACS Medicinal Chemistry Letters.   Dr. Reynolds earned a BA, with honors, from Austin College and PhD from the University of Texas at Austin.  He has published approximately 100 papers, patents, and book chapters, and is a co-editor of two books.  His comments on drug discovery have been sought by news organizations ranging from C&E News to the Wall Street Journal.

Session Chairs

Non-Profit Research: Dr. Christopher Cooper

Dr. Cooper received his BS (magna cum laude) in Chemistry from Clemson University in 1980, and his MS in Organic Chemistry at Stanford University with Professor Carl Djerassi in 1982. Following a two-year industry sabbatical at CIBA-Geigy Pharmaceuticals (now Novartis), he returned to Stanford in 1984 to earn his Ph.D. in Organic Chemistry with Professor Paul A. Wender. From 1988 through 1998, Dr. Cooper was engaged in medicinal chemistry research at Pfizer, Inc., at both their Groton, Connecticut, and Sandwich, England, laboratories.  In 1998, Dr. Cooper accepted a position with Bristol-Myers Squibb, Inc., in Princeton, New Jersey, to launch the Lead Synthesis Group (Early Discovery Chemistry), and to oversee the design, development, and synthesis of novel, drug-like medicinal chemistry arrays.  Dr. Cooper joined the Global Alliance for TB Drug Development (TB Alliance) in January, 2009, and is currently serving as Senior Director, Chemistry.  His responsibilities include direction of all lead identification, lead optimization, pre-clinical and clinical candidate chemistry efforts across TB Alliance’s drug discovery portfolio.  Dr. Cooper has over 60 publications, presentations, and patents, and he currently serves on the scientific advisory boards for Anacor Pharmaceuticals/Bill and Melinda Gates Foundation, Eli Lilly TB Drug Discovery Initiative, Weill Cornell Medical Center TB Research Unit, and the Maurice Wilkins Centre for Molecular Biodiscovery [New Zealand].

Natural Products: Dr. Cedric Pearce

Cedric Pearce obtained B.Sc. and Ph.D. degrees from the University of Southampton, UK. His current major interest is new drug discovery and development, and entrepreneurship in the life sciences. Following post-doctoral appointments in France (Royal Society European Exchange Fellow at C.N.R.S.) and the University of Illinois at Urbana/Champaign (School of Chemical Sciences), he was a faculty member in the Department of Medicinal Chemistry and Pharmacognosy at the University of Connecticut. In the 1990s he joined American Cyanamid’s medical and agricultural natural products discovery program and since that time has worked in the biotechnology industry, both as a scientist and from the investment perspective.  In 2001 he founded Mycosynthetix Inc. a fungus metabolites research company. Mycosynthetix has been involved with the discovery and development of biologically-active fungal metabolites for a variety of applications, and currently has projects in the fields of agriculture (including the development of the herbicide, mevalocidin), cancer, and infectious diseases (including a project to find new medicines for the free-living parasitic amoebae Naegleria fowleri, funded by NIAID). He has (co)authored >200 publications, patents, chapters and conference abstracts, with approximately half addressing biologically-active fungal products and half addressing bacterial products, largely antibiotics . He is an editor for the Journal of Natural Products and MYCOSCIENCE. He is currently Vice President (and, in 2017, President) of the American Society of Pharmacognosy, a leading natural products research society.

Confirmed Speakers

Roberto Berlinck (Instituto de Química de São Carlos)
Guy Breitenbucher 
(Dart NeuroScience)
Barry Bunin (Collaborative Drug Discovery)
Jeremy Burrows 
(MMV)
Guy Carter (Carter-Bernan Consulting)
Christopher Cooper (TB Alliance)
Scott Dax (BioMotiv)
Bart Decorte (Kodib)
Manu De Rycker (University of Dundee)
Jose Fernandez (Signum Biosciences )
Leah Frye (Schrödinger)
Rachel Garlish (UCB)
Mark Hamann (Medical University of South Carolina)
William Jorgensen (Yale University)
John Kulp (Blumberg Institute)
Kevin Madauss (GSK)
Stephen Martin (University of Texas at Austin)
Jose Medina (Universidad Nacional Autonoma de Mexico)
Nicholas Oberlies (The University of North Carolina at Greensboro)
Cedric Pearce (Mycosynthetix)
Ronald Quinn (Griffith University)
Janet Ralbovsky (Dana-Farber Cancer Institute)
Andrea L.C. Reid (Dechert LLP)
Dagmar Ringe (Brandeis University)
Matthew Segall (Optibrium)
Garry Smith (Fox Chase Chemical Diversity Center)
Ted Torphy (Biomotiv)
Sandor Vajda (Boston University)
Peter Warner (Bill and Melinda Gates Foundation)
Bob Wenslow (Crystal Pharmatech)



 

Sponsors

Sponsors

Report

The third Drug Discovery Re-Invented Meeting focused on the science, structure, and business of drug discovery today with an emphasis on how it is being accomplished outside the traditional large pharmaceutical company model.   The meeting brought together experts in medicinal chemistry, biology, structure-based drug design, computational chemistry, novel technology platforms, and natural products discovery.

The meeting was chaired by William Kinney (President, IteraMed Consulting LLC), Charles Reynolds (President, Gfree Bio LLC), Cedric Pearce (CEO/CSO, Mycosynthetix), and Christopher Cooper (Senior Director of Chemistry, TB Alliance).

Day 1 started with a Keynote Address, delivered by Ted Torphy (CSO, BioMotiv).  This very informative analysis of the changing drug discovery landscape was titled “In Theory, the Model is Brilliant – Learnings from the Harrington Project, a New Disruptive Model of R&D.”  Ted’s talk set the tone for the meeting.  Day 1 continued with the “New Approaches in Biotech, Pharma, and Academia” session with talks from Guy Breitenbucher (Dart NeuroScience), Bob Wenslow (Crystal Pharmatech), Kevin Madauss (GlaxoSmithKline), Jose Fenandez (Signum Biosciences), Garry Smith (Fox Chase Chemical Diversity Center), and Stephen Martin (University of Texas at Austin).  Important topics for discussion included fatty acid amide hydrolase inhibitors; the importance of defining crystalline forms in early development; an alternative discovery and development model in Latin America; developing novel technologies spanning opportunities in dermatology and neurology; development of small molecules to treat Epstein-Barr virus associated diseases; and applications of chemistry to unmet needs in neuroscience.

Day 2, the international AM session on “Natural Products” was chaired by Cedric Pearce who emphasized the medical and commercial impact of natural products such as Taxol and the Statins.  The session included presentations by Nicholas Oberlies (University of North Carolina at Greensboro), Roberto Berlinck (Instituto de Quimica de São Carlos), Jose Medina-Franco (Universidad Nacional Autonoma de Mexico), Guy Carter (Carter-Berman Consulting), Mark Hamann (Medical University of South Carolina), Ronald Quinn (Griffith University) and Andreas Vilcinkas (Univeristy of Gießen).  Highlights included the delivery of hydrophobic natural products by pH release from nanoparticles; progress on leishmaniasis and chagas disease in Brazil;  methods of defining diversity in natural products; fungal metabolites; algae derived natural products; fragment based discovery using natural products; and gram negative antibiotics from insects. The PM session on “Non-profit Drug Discovery” was chaired by Christopher Cooper and featured Peter Warner (Bill and Melinda Gates Foundation), Leah Frye (Schrödinger), Jeremy Burrows (MMV), Manu De Rycker (University of Dundee), Barry Bunin (Collaborative Drug Discovery), and Christopher Cooper (TB Alliance).   The non-profit session was focused on the diseases of the developing world including malaria, river blindness, tuberculosis, and new structure-based methods using water mapping and FEP.

On Day 3, the “Structure, Modeling, and Fragment-Based Design” session started with one of the pioneers in fragment-based design, Dagmar Ringe (Brandeis).  Her talk was followed by Bill Jorgensen (Yale), John Kulp (Connifer Point), Chuck Reynolds (Gfree Bio), Matt Segall (Optibrium), and Sandor Vajda (Boston University).  Highlights included research in Alzheimers disease targeting Vacuolar Protein Sorting Gene that controls trafficking of proteins to the lysosome; in cancer by modulation of Macrophage Migration Inhibitory Factor; in a user friendly, affordable and powerful web-based fragment based drug design platform; in the importance of ligand efficiency factoring in the size of the target protein; a powerful database analysis tool; in web-based informatics innovations; and in hot spot analysis for druggability and fragment binding. This session was followed by a group snorkeling trip through a well preserved coral marine park.

The day continued with a session on “New Tools and Technologies” that featured lectures by lead snorkeler Rachel Garlish (UCB), Andrea Reid (Dechert LLP), and Janet Ralbovsky (Dana-Farber Cancer Institute).  Important topics included native and hydrogen deuterium MS techniques for evaluating interactions of small molecules with their target proteins; recent developments in court cases on “obviousness” when determining the patentability of new discoveries; and the interface between drug discovery and commercialization at the Dana-Farber Cancer Institute.  This session was followed by the poster session and a very popular breakout discussion with acclaimed patent attorney Andrea Reid.   

Day 4, “Non-Traditional Targets and Approaches” continued with presentations by Scott Dax (BioMotiv), Barte DeCorte (Kodib), and one of the student travel award winners, Chao Wang (Griffith Institute for Drug Discovery). Presentations included a peroxynitrite quenching molecule for the treatment of inflammatory pain that also helps with opiate tolerance and is opiate sparing; and the power of novel chemical space derived from natural products combined with diverse phenotypic model systems.

The meeting was extremely interactive with enthusiastic question and answer sessions following each talk (so much so it was hard to stay on time).  This meeting remains unique with respect to the breadth of participants and focus on new approaches to discovering drugs.

Programme

TUESDAY 21ST FEBRUARY 2017

13:15 – 14:15

Registration & Reception

13:15 – 14:15

Welcome Lunch
*Kalmia Buffet Restaurant*

14:15 – 14:30

Opening Comments

NEW APPROACHES IN BIOTECH AND ACADEMIA
Session Chair:  Chuck Reynolds, Gfree Bio

14:30 – 15:15

Ted Torphy
Biomotiv

“IN THEORY, THE MODEL IS BRILLIANT” – LEARNINGS FROM THE HARRINGTON PROJECT, A NEW DISTRIBUTIVE MODEL OF R&D

15:15 – 15:45

Guy Breitenbucher
Dart NeuroScience

REFLECTING ON FATTY ACID AMIDE HYDROLASE (FAAH): A LOOK BACK AT A SUCCESSFUL ACADEMIC-INDUSTRIAL COLLABORATION IN DRUG DISCOVERY

15:45 – 16:15

Bob Wenslow
Crystal Pharmatech

DON’T OVERLOOK KEY PRECLINICAL RESEARCH IN EARLY PHARMACEUTICAL DEVELOPMENT

16:15 – 16:45

Refreshments

NEW APPROACHES IN BIOTECH AND ACADEMIA
Session Chair:  William Kinney, IteraMed Consulting

16:45 – 17:15

Kevin Madauss
GlaxoSmithKline

GSK’s TRUST IN SCIENCE PROGRAM: AN ALTERNATIVE DISCOVERY AND DEVELOPMENT MODEL IN LATIN AMERICA

17:15 – 17:45

Jose Fernandez
Signum Biosciences

FROM CONSUMER PRODUCTS TO DRUGS: DEVELOPING NOVEL TECHNOLOGIES IN DERMATOLOGY AND NEUROLOGY

17:45 – 18:15

Garry Smith
Fox Chase Chemical Diversity Center

DRUG DISCOVERY AT THE ACADEMIC/BIOTECH START-UP INTERFACE: DEVELOPMENT OF SMALL MOLECULES TO TREAT EPSTEIN-BARR VIRUS-ASSOCIATED DISEASES, CONTINUED

18:15 – 18:45

Stephen Martin
University of Texas at Austin

APPLICATIONS OF CHEMISTRY TO UNMET MEDICAL NEEDS IN NEUROSCIENCE

18:45

Dinner at Leisure & Free Time

WEDNESDAY 22ND FEBRUARY 2017

07:00 – 08:15

Breakfast

*Kalmia Buffet Restaurant*

NATURAL PRODUCTS SESSION
Session Chair:  Cedric Pearce, Mycosynthetix

08:15 – 08:30

Cedric Pearce
Mycosynthetix

INTRODUCTORY COMMENTS

08:30 – 09:15

Nicholas Oberlies
The University of North Carolina at Greensboro

ANTICANCER DRUG LEADS FROM NATURAL SOURCES: STRATEGIES, PROGRESS, AND INNOVATIVE TECHNIQUES

09:15 – 09:45

Roberto Berlinck
Instituto de Química de São Carlos

DISCOVERY AND SAR INVESTIGATIONS OF ANTI-PARASITIC ALKALOIDS

09:45 – 10:15

Jose Medina
Universidad Nacional Autonoma de Mexico

CHEMINFORMATICS ANALYSIS OF THE CHEMICAL SPACE OF NATURAL PRODUCTS FOR DRUG DISCOVERY

10:15 – 10:45

Refreshments & Group Photo

10:45 – 11:15

Guy Carter
Carter-Bernan Consulting

LEVERAGING THE CHEMICAL DIVERSITY OF AQUATIC MICROBIOMES

11:15 – 11:45

Mark Hamann
Medical University of South Carolina

NUISANCE AND HARMFUL ALGAL BLOOMS: AN EMERGING SOURCE FOR DRUG DISCOVERY AND DEVELOPMENT

11:45 –12:15

Ronald Quinn
Griffith University

FRAGMENT-BASED DRUG DISCOVERY USING NATURAL PRODUCTS

12:15 –12:45

Andreas Vilcinskas
Fraunhofer IME

THE SANOFI-FRAUNHOFER CENTER FOR NAURAL PRODUCT RESEARCH

12:45 – 16:15

Lunch at Leisure & Free Time

NON-PROFIT SECTOR IN DRUG DISCOVERY AND DEVELOPMENT
Session Chair: Christopher Cooper, TB Alliance

16:15 – 16:45

Peter Warner
Bill and Melinda Gates Foundation

DRUG DISCOVERY FOR NEGLECTED DISEASES: IMPORTANCE OF PARTNERSHIPS

16:45 – 17:15

Leah Frye
Schrödinger

STRUCTURE-BASED DRUG DISCOVERY IN THE NON-PROFIT SECTOR

17:15 – 17:45

Jeremy Burrows
MMV

DRUG DISCOVERY TO CONTROL AND ERADICATE MALARIA

17:45 – 18:15

Refreshments

18:15 – 18:45

Manu De Rycker
Drug Discovery Unit, University of Dundee

DISCOVERY AND LEAD-OPTIMISATION OF A PROMISING NEW ANTILEISHMANIAL COMPOUND SERIES WITHIN AN ACADEMIC-INDUSTRY PARTNERSHIP

18:45 – 19:15

Barry Bunin
Collaborative Drug Discovery

PRESENT AND FUTURE COLLABORATIVE DRUG DISCOVERY INFORMATICS INNOVATIONS

19:15 – 19:45

Christopher B. Cooper
TB Alliance

ANTITUBERCULAR 3-(4-AMINOPHENYL)OXAZOLIDIN-2-ONES: PROGRESS TOWARDS BETTER, SAFER TB AGENTS

19:45

Dinner at Leisure & Free Time

THURSDAY 23RD FEBRUARY 2017

07:00 – 08:30

Breakfast

*Kalmia Buffet Restaurant*

STRUCTURE, MODELING, AND FRAGMENT-BASED DESIGN SESSION
Session Chair: Chuck Reynolds, Gfree Bio

08:30 – 09:00

Dagmar Ringe
Brandeis

CHEMICAL CHAPERONES AS AN APPROACH TO TREAMENT OF ALZHEIMER’S DISEASE

09:00 – 09:30

Bill Jorgensen
Yale

COMPUTER-AIDED DISCOVERY OF ENZYME INHIBITORS

09:30 – 10:00

John Kulp
Conifer Point

AN OPEN WEB SERVICE FOR FRAGMENT-BASED DESIGN OF SMALL MOLECULES

10:00 – 10:30

Refreshments

10:30 – 11:00

Chuck Reynolds
Gfree Bio

RETHINKING LIGAND EFFICIENCY

11:00 – 11:30

Matt Segall
Optibrium

SEAMLESS INTEGRATION OF 3D STRUCTURE-BASED DESIGN AND 2D STRUCTURE-ACTIVITY RELATIONSHIPS TO GUIDE MEDICINAL CHEMISTRY

11:30 – 12:00

Sandor Vajda
Boston University

HOT SPOT ANALYSIS FOR DRUGGABILITY AND FRAGMENT BINDING

12:00 – 16:00

Lunch at Leisure & Free Time

DRUG DISCOVERY AND DEVELOPMENT TOOLS AND TECHNOLOGIES

Session Chair:  Bill Kinney, IteraMed Consulting

16:00 – 16:30

Rachel Garlish
UCB

NATIVE AND HYDROGEN DEUTERIUM MASS SPECTROMETRY IN DRUG DISCOVERY

16:30 – 17:00

Andrea L.C. Reid
Dechert LLP

FOUNDATIONS OF PATENT LAW: OBVIOUSNESS

17:00 – 17:30

Janet Ralbovsky
Dana-Farber Cancer Institute

DRUG DISCOVERY AND COMMERCIALIZATION AT THE DANA-FARBER CANCER INSTITUTE

17:30 – 17:50

Martina Sutovska
Comenius University and BioMed

ECHINACEA PURPUREA - A SOURCE OF GLYCOCONJUGATE WITH BRONCHODILATING AND ANTI-INFLAMMATORY EFFECTS

17:50 – 19:00

Poster Session & Refreshments

17:50 – 19:00

Andrea Reid (Dechert LLP) IP Breakout Session

19:30

*Gala Dinner & Poster Awards*

FRIDAY 24TH FEBRUARY 2017

07:00 – 08:30

Breakfast

*Kalmia Buffet Restaurant*

NON-TRADITIONAL TARGETS AND APPROACHES
Session Chair: Chuck Reynolds, Gfree Bio

08:30 – 09:00

Scott Dax
BioMotiv

PHENOTYPIC SCREENING AND ANTI-OXIDANT ASSAYS LEADING TO THE DISCOVERY OF A NOVEL CLASS OF ANALGESICS

09:00 – 09:30

Bart DeCorte
Kodib

NATURAL-PRODUCT DERIVED NOVEL CHEMICAL SPACE – A POWERFUL STARTING POINT IN DRUG DISCOVERY

STUDENT PRESENTATIONS
Session Chair: Bill Kinney, IteraMed Consulting

09:30 – 09:50

Chao Wang
Griffith Institute for Drug Discovery

MEET THE CHALLENGE: PROBING PARKINSON’S DISEASE BIOLOGY BY INTEGRATED MULTIDISCIPLINARY METHODOLOGY

 

09:50 – 10:10

Xioayan Chen
Medical University of South Carolina

EXPLORATION OF DRUG LEADS FROM THE HUMAN MICROBIOME: AKKERMANSIA MUCINIPHILA

10:10 – 10:25

Closing Comments

Speakers

Invited Speakers

  • Prof. Stephen Martin
    Professor, The University of Texas
  • Dr. Theodore Torphy
    Chief Science Officer, BioMotiv LLC
  • Prof. Roberto G. S. Berlinck
    Full Professor, Universidade de São Paulo
  • Dr. Robert Wenslow
    VP Business Development, Crystal Pharmatech, INC
  • Prof. William Jorgensen
    Sterling Professor, Yale University
  • Ms. Andrea Reid
    Partner, Patent Counseling and Prosecution, Dechert LLP
  • Dr. Leah Frye
    Vice President, Schrodinger
  • Dr. Scott Dax
    Project Director, BioMotiv
  • Dr. Janet Ralbovsky
    Sr. Licensing Associate, Dana-Farber Cancer Institute
  • Dr. Guy Carter
    Chief Scientific Officer, Biosortia Pharmaceuticals
  • Dr. Matthew Segall
    CEO, Optibrium Ltd
  • Dr. Kevin Madauss
    Programme Manager: Trust in Science, GlaxoSmithKline
  • Dr. Jose Medina-Franco
    Professor, Universidad Nacional Autonoma de Mexico
  • Dr. Peter Warner
    Senior Prorgam Officer, Bill & Melinda Gates Foundation
  • Prof. Ronald Quinn
    Professor, Griffith University
  • Dr. Barry Bunin
    CEO, Collaborative Drug Discovery
  • Dr. Mark Hamann
    Professor of Drug Discovery and Biomedical Sciences, MUSC
  • Prof. Dagmar Ringe
    professor, Brandeis Univiversity
  • Dr. Manu De Rycker
    Portfolio Leader Kinetoplastids, University of Dundee
  • Prof. John Kulp
    CEO, Conifer Point
  • Dr. Rachel Garlish
    Senior Principle Scientist, UCB
  • Dr. Jeremy Burrows
    VP, Head of Drug Discovery, Medicines for Malaria Venture
  • Dr. James Breitenbucher
    Director of Chemistry, Dart Neuroscience
  • Dr. Bart DeCorte
    President, Kodib
  • Dr. Garry Smith
    Director of Chemistry, Fox Chase Chemical Diversity Center
  • Dr Nicholas Oberlies
    Professor , UNCG
  • Dr. Jose Fernandez
    Director of R&D, Signum Dermalogix, Inc.

Feedback

Sign In

Your feedback has been received.

Cant see images? See gallery on Flickr